European Journal of Cancer
Volume 41, Issue 18 , Pages 2846-2852 , December 2005

Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma

  • Jos A.M. Bramer

      Affiliations

    • Royal Orthopaedic Hospital, Bristol Road South, Northfield, Birmingham B31 2AP, UK
    • Department of Orthopaedic Surgery G4-222, Academic Medical Center, Meibergdreef 9, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 204723023; fax: +31 205669117.
    • ,
  • Adesegun A. Abudu

      Affiliations

    • Royal Orthopaedic Hospital, Bristol Road South, Northfield, Birmingham B31 2AP, UK
    • ,
  • Roger M. Tillman

      Affiliations

    • Royal Orthopaedic Hospital, Bristol Road South, Northfield, Birmingham B31 2AP, UK
    • ,
  • Simon R. Carter

      Affiliations

    • Royal Orthopaedic Hospital, Bristol Road South, Northfield, Birmingham B31 2AP, UK
    • ,
  • Vaiyapuri P. Sumathi

      Affiliations

    • Royal Orthopaedic Hospital, Bristol Road South, Northfield, Birmingham B31 2AP, UK
    • ,
  • Robert J. Grimer

      Affiliations

    • Royal Orthopaedic Hospital, Bristol Road South, Northfield, Birmingham B31 2AP, UK

Received 27 May 2005 ,Revised 12 July 2005 ,Accepted 27 July 2005.

References 

  1. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the multi-institutional osteosarcoma study. Clin Orthopaed Rel Res. 1991;(270):
  2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790
  3. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the memorial hospital experience. Cancer. 1992;69:698–708
  4. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911–917
  5. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–4027
  6. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423–431
  7. Bacci G, Picci P, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer. 1993;71:1224–1230
  8. Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep. 2002;9:171–175
  9. Stokkel MP, Linthorst MF, Borm JJ, et al. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J Cancer Res Clin Oncol. 2002;128:393–399
  10. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at flie Rizzoli Institute. Ann Oncol. 2001;12:1145–1150
  11. Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenie sarcoma receiving chemotherapy. Cancer. 1979;43:2178–2181
  12. Juergens H, Kosloff C, Nirenberg A, et al. Prognostic factors in the response of primary osteogenic sarcoma to pre-operative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monogr. 1981;221–226
  13. Pochanugool L, Subhadharaphandou T, Dhanachai M, et al. Prognostic factors among 130 patients with osteosarcoma. Clin Orthopaed Rel Res. 1997;(345):
  14. Bramwell VH, Steward WP, Nooij M, et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol. 1999;17:3260–3269
  15. Rosen G, Caparros B, Huvos AG, et al. Pre-operative chemotherapy for osteogenic sarcoma: selection of post-operative adjuvant chemotherapy based on the response of the primary tumor to pre-operative chemotherapy. Cancer. 1982;49:1221–1230
  16. Fletcher CDM, Unni KK, Mertens F. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. WHO classification of bone tumours. Lyon: IARC Press; 2002;
  17. Bielack S, Kempf-Bielack B, Schwenzer D, et al. Neoadjuvant therapy for localized extremity osteosarcoma. Experience of the Cooperative Osteosarcoma Study Group COSS with 925 patients. Klinische Padiatrie. 1999;211:260–270
  18. Van der Woude HJ, Bloem JL, Verstraete KL, et al. Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol. 1995;165:593–598
  19. Bramer JA, Gubler FM, Maas M, et al. Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma. Pediatr Radiol. 2004;34:614–619
  20. Schwartz MK. Biochemical procedures as aids in diagnosis of different forms of cancer. Ann Clin Lab Sci. 1974;4:95–103
  21. Singh I, Tsang KY, Ludwig GD. Alkaline phosphatase and ultrastructural alterations in human osteosarcoma cells in tissue culture. Eur Surg Res. 1974;6:247–263
  22. Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients pre-operatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658–663
  23. Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer. 2002;38:1218–1225

PII: S0959-8049(05)00805-1

doi: 10.1016/j.ejca.2005.07.024

European Journal of Cancer
Volume 41, Issue 18 , Pages 2846-2852 , December 2005

Article Tools

* Image Usage & Resolution